Cardior announces first patient dosed in phase 2 trial
The HF-REVERT study is evaluating efficacy and safety of heart failure therapy
Read More
Tag: Cardior
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
